Related Experiment Video
Updated: Aug 6, 2026
06:10
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
Published on: March 30, 2020
Engineering Concentration-Dependent Intravitreal Mobility via Cyclic Arginine-Enriched Nanocarrier Surface
Maximilian Hammer1,2, Bryan Calder Ackermann1, Anna Stoß1
1David J Apple Laboratory for Vision Research and University Eye Clinic Heidelberg, Heidelberg, Germany.
Advanced Healthcare Materials
|August 5, 2026
Summary
Positively charged nanoparticles reduce mobility within the eye, minimizing visual disturbances for sustained drug delivery. This cyclic-arginine surface modification enhances ocular drug delivery system safety and efficacy.
Area of Science:
- Ophthalmology
- Biomaterials Science
- Nanotechnology
Background:
- Intraocular drug delivery faces challenges with nanoparticle migration towards the visual axis, causing light scattering.
- The vitreous humor's negative charge offers a target for surface-engineered nanoparticles to control mobility.
Purpose of the Study:
- To evaluate the in vivo performance and biocompatibility of cyclic-arginine surface-functionalized liposomal nanocarriers for sustained intraocular drug delivery.
- To assess the concentration-dependent effect of cyclic-arginine modification on nanoparticle intravitreal mobility.
Main Methods:
- A 6-week in vivo study in a large animal pig model using intravitreally administered liposomes with varying concentrations of cyclic-arginine modification.
- Multimodal assessment including intraocular pressure monitoring, fundus imaging, OCT, angiography, and retinal immunostainings.
Main Results:
- Cyclic-arginine surface functionalization demonstrated a concentration-dependent reduction in nanoparticle intravitreal mobility.
- Vitreous haze and fundus-based distribution analyses quantified the decreased mobility.
- All tested formulations exhibited excellent ocular biocompatibility with no structural or vascular adverse effects.
Conclusions:
- Cyclic-arginine surface modification is an effective strategy to control nanoparticle mobility within the vitreous.
- This approach supports the development of advanced nanoparticle biomaterials for long-acting ophthalmic drug delivery.
